New J-code for EpioxaTM, J2789, set to become effective July 1, 2026 April 15, 2026 Glaukos Corporation (NYSE: GKOS) announced the U.S....
The first and only FDA-approved, incision-free, topical drug therapy for keratoconus March 19, 2026 Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and...
Options expand for patients in need of gas permeable contact lenses.
Topography innovation in optometry.
Mastering patient flow for specialty contact lens patients.
Growing a profitable medically necessary contact lens niche.
Correcting mistakes when billing for medically necessary contact lenses.
Pushing care & profitability to new heights.
Investments that change patient care & profitability.
Targeting in-office medical service messaging to individual patient needs.
Transformative myopia management technology.
Finding an organization to partner with that accelerates specialized care.
A webinar to help you up your game in keratoconus diagnosis & management.
Building blocks of a thriving scleral lens practice.
Technology that is changing one practice's trajectory.
Learning exactly what your patients experience in your office.
Educating patients so they understand the value of specialty CL lenses.
Finding a buyer that will take specialty CL services to the next level.
Tips on making scleral lenses a profitable, fast-growing sector of your practice.
Keys to building your special CL care.
Making services for hard-to-fit CL patients a win-win.